“In sight, in mind.” If the December issue of GEN has a theme, that’s it. Consider our cover story, which focuses on super-resolution microscopy technologies. Not only are they visualizing what was once too small to visualize, they are also generating data to clarify the relationships between molecules, revealing interactions and pathways of interest to drug developers. And just as seeing induces knowing, knowing can induce seeing, as when AI sifts through data to help drug developers “see” the vulnerabilities of high-value targets and the structural features that advantage some drug candidates over others. This “in mind, in sight” theme is developed in an article that summarizes a discussion from The State of AI in Drug Discovery, a GEN virtual summit. The theme is also evident in this issue’s A-List, “Ten Companies to Watch in AI Drug Discovery.” Other insightful content in this issue includes an interview with Illumina’s CEO, Jacob Thaysen.